Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI

{
  "signal_id": "63c2f058-2e68-0f10-17c2-b470463dcb84",
  "signal_type": "news",
  "signal_subtype": "invests_into",
  "detected_at": "2026-09-12T10:32:00+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "url": "https://www.proactiveinvestors.com/companies/news/1098450/medicus-pharma-ceo-on-skinject-and-pfizer-partnership-icymi-1098450.html",
    "title": "Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI - Proactive financial news",
    "excerpt": "Proactive has a commercial relationship with Medicus Pharma. This article was produced independently under Proactive's Editorial Standards Policy . Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. She earned a Bachelor of... Read more Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to...",
    "product": "CD228-targeted antibody-drug conjugate",
    "summary": "Pfizer is providing $2 million in development funding to Medicus Pharma as part of their co-development and licensing partnership for a CD228-targeted antibody-drug conjugate.",
    "planning": false,
    "image_url": "https://cdn.proactiveinvestors.com/eyJidWNrZXQiOiJwYS1jZG4iLCJrZXkiOiJ1cGxvYWRcL05ld3NcL0ltYWdlXC8yMDI2XzA5XC9QaGFybWFjZXV0aWNhbC1iaW90ZWNobm9sb2d5LW1lZGljaW5lLXByb2R1Y3Rpb24tbGFiLXNjaWVuY2VfNmFhNDExNTkyZDdkYi5qcGciLCJlZGl0cyI6eyJyZXNpemUiOnsid2lkdGgiOjEyMDAsImhlaWdodCI6NjMwLCJmaXQiOiJjb3ZlciJ9fX0=",
    "confidence": 0.9,
    "product_data": {
      "name": "CD228-targeted antibody-drug conjugate",
      "full_text": "CD228-targeted antibody-drug conjugate",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-12T10:32:00Z",
    "article_sentence": "Bokhari said the Pfizer relationship came with $2 million in development funding as well as inventory and infrastructure support.",
    "amount_normalized": 2000000,
    "financing_type_tags": [
      "equity"
    ],
    "related_company_name": "Medicus Pharma",
    "related_company_domain": "medicuspharma.com"
  }
}

curl https://signals.autobound.ai/v1/signals/63c2f058-2e68-0f10-17c2-b470463dcb84 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","limit":20}'